However, unlike the tumor Foundation One CDx panel, the Foundation One Liquid CDx panel is indicated as a companion diagnostic specifically for targeted therapies in NSCLC (tyrosine kinase inhibitors against EGFR, ALK, MET) and not yet applicable to immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.